5 Best Diabetes Stocks To Buy Now

3. Zealand Pharma A/S (OTC:ZLDPF)

Number of Hedge Fund Holders: N/A

Zealand Pharma A/S (OTC:ZLDPF) is a Denmark-based biotechnology company manufactures and markets peptides-based medicines in Denmark, and its product portfolio includes Dasiglucagon, a diabetes management injection that works by causing the liver to release stored sugar to the blood. 

On September 9, Morgan Stanley analyst Sarita Kapila initiated coverage of Zealand Pharma A/S (OTC:ZLDPF) with an Overweight rating and a DKK 179 price target. The analyst expects short-term pipeline reviews to support share outperformance and sees a positive risk/reward with the market cautious. Zealand Pharma A/S (OTC:ZLDPF) is primarily a three-asset company, with its wholly owned obesity pipeline overlooked, which represents “free” optionality, the analyst wrote in a research note.